AbbVie’s Study on Mitigating Ocular Toxicity in Ovarian Cancer Treatment

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 2 study titled ‘A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression.’ The study aims to assess the incidence and severity of ocular adverse events related to mirvetuximab soravtansine in patients with recurrent ovarian cancer, focusing on those with high folate receptor-alpha expression. This research is significant as it explores strategies to mitigate eye-related side effects, potentially improving treatment outcomes for these patients.

The intervention being tested involves two experimental arms: one using primary prophylactic steroid eye drops and the other using vasoconstricting eye drops, both in combination with mirvetuximab soravtansine. The purpose is to evaluate which strategy better mitigates ocular toxicity.

The study employs a randomized, parallel assignment design with no masking, focusing on treatment as the primary purpose. Participants are assigned to one of the two intervention arms to compare the effectiveness of the ocular toxicity mitigation strategies.

The study began on July 29, 2024, and the last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.

This study could influence AbbVie’s stock performance by potentially enhancing the safety profile of mirvetuximab soravtansine, making it more attractive to investors. As ocular toxicity is a common concern with such treatments, successful mitigation strategies could set AbbVie apart from competitors in the oncology market.

The study is currently ongoing, with further details available on the ClinicalTrials portal.